A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors.

被引：0
|
作者：
Pandite, L
Burris, HA
Jones, S
Wilding, G
Taylor, C
Versola, MJ
Smith, DA
Stead, A
Koch, KM
Spector, NL
机构：
[1] GlaxoSmithKline, Res Triangle Pk, NC USA
[2] Sarah Cannon Canc Ctr, Nashville, TN USA
[3] Wisconsin Comprehens Canc Ctr, Madison, WI USA
[4] Arizona Canc Ctr, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3179
引用
收藏
页码：238S / 238S
页数：1
相关论文
共 50 条
  • [31] Efficacy, safety, tolerability and price of newly approved drugs in solid tumors.
    Barnes, Tristan Alexandra
    Amir, Eitan
    Templeton, Arnoud J.
    Garcia, Susana Gomez
    Navarro, Beatriz
    Seruga, Bostjan
    Ocana, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Phase I and pharmacokinetic study of farletuzumab in solid tumors.
    Sasaki, Yasutsuna
    Miwa, Keisuke
    Yamashita, Keishi
    Fujiwara, Keiichi
    Katsumata, Noriyuki
    Fujiwara, Yasuhiro
    Namiki, Masayuki
    Koyanagi, Nozomu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Dose escalation and pharmacokinetic (pk) study of E 7389, a microtubule-hinding drug in patients (pts) with advanced solid tumors.
    Desai, KK
    Goel, S
    Mita, A
    Silberman, S
    Sicam, J
    Woeppel, S
    Macapinlac, M
    Berg, K
    Rowinski, E
    Mani, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 214S - 214S
  • [34] A phase I and pharmacokinetic (PK) study of high dose selenomethionine (SLM) in combination with irinotecan (IRI) in patients with advanced solid tumors.
    Rustum, Y
    Pendyala, L
    Creaven, PJ
    Smith, P
    Azrak, R
    Cao, S
    Durrani, F
    Lawrence, DD
    Badmaev, V
    Diane, NC
    Fakih, MG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 154S - 154S
  • [35] Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
    Goldman, Jonathan Wade
    Piha-Paul, Sarina Anne
    Curti, Brendan D.
    Pedersen, Katrina
    Bauer, Todd Michael
    Groenland, Stefanie L.
    Carvajal, Richard D.
    Chhaya, Vaishali
    Hammond, Scott A.
    Streicher, Katie
    Townsley, Danielle Michelle
    Chae, Young Kwang
    Voortman, Jens
    Marabelle, Aurelien
    Powderly, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] A phase I dose escalation study of the dual kinase inhibitor GW572016 in combination with paclitaxel
    Jones, SF
    Burris, HA
    Willcutt, NT
    Dickson, NR
    Raefsky, EL
    Greco, A
    Versola, MJ
    Smith, DA
    Pandite, LN
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S83 - S83
  • [37] Phase I study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors.
    Xu, B.
    Shen, L.
    Ye, D.
    Jappe, A.
    Wang, H.
    Yuan, R.
    Wu, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors.
    Simonelli, M.
    Zucali, P. A.
    De Sanctis, R.
    Lorenzi, E.
    De Vincenzo, F.
    Rimassa, L.
    Tronconi, M. C.
    Personeni, N.
    Masci, G.
    Zuradelli, M.
    Perrino, M.
    Bertossi, M.
    Giordano, L.
    Santoro, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] A phase II trial of lapatinib (GW572016) in patients with recurrent prostate cancer as evident by a rising PSA
    Chen, Y.
    Wilding, G.
    Gee, J.
    DiPaola, R. P.
    Pins, M.
    Carducci, M. A.
    Stein, M. N.
    Bubley, G.
    Liu, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Phase I pharmacokinetic (PK) and safety study of intravenous (IV) Cl-1033 in patients with advanced solid tumors
    Simon, GR
    Olson, S
    Garrett, CR
    Eiseman, I
    Langevin, M
    Mahany, JJ
    Sullivan, DM
    Schlicht, MG
    Lush, R
    Lanehan, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 209S - 209S
12345